Cargando…

Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey

The Covid-19 pandemic required many clinical trials to adopt a decentralized framework to continue research activities during lock down restrictions. The STOPCoV study was designed to assess the safety and efficacy of Covid-19 vaccines in those aged 70 and above compared to those aged 30–50 years of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ravindran, Rizani, Szadkowski, Leah, Lovblom, Leif Erik, Clarke, Rosemarie, Huang, Qian Wen, Manase, Dorin, Parente, Laura, Walmsley, Sharon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168576/
https://www.ncbi.nlm.nih.gov/pubmed/37159470
http://dx.doi.org/10.1371/journal.pdig.0000242
_version_ 1785038882586230784
author Ravindran, Rizani
Szadkowski, Leah
Lovblom, Leif Erik
Clarke, Rosemarie
Huang, Qian Wen
Manase, Dorin
Parente, Laura
Walmsley, Sharon
author_facet Ravindran, Rizani
Szadkowski, Leah
Lovblom, Leif Erik
Clarke, Rosemarie
Huang, Qian Wen
Manase, Dorin
Parente, Laura
Walmsley, Sharon
author_sort Ravindran, Rizani
collection PubMed
description The Covid-19 pandemic required many clinical trials to adopt a decentralized framework to continue research activities during lock down restrictions. The STOPCoV study was designed to assess the safety and efficacy of Covid-19 vaccines in those aged 70 and above compared to those aged 30–50 years of age. In this sub-study we aimed to determine participant satisfaction for the decentralized processes, accessing the study website and collecting and submitting study specimens. The satisfaction survey was based on a Likert scale developed by a team of three investigators. Overall, there were 42 questions for respondents to answer. The invitation to participate with a link to the survey was emailed to 1253 active participants near the mid-way point of the main STOPCoV trial (April 2022). The results were collated and answers were compared between the two age cohorts. Overall, 70% (83% older, 54% younger cohort, no difference by sex) responded to the survey. The overall feedback was positive with over 90% of respondents answering that the website was easy to use. Despite the age gap, both the older cohort and younger cohort reported ease of performing study activities through a personal electronic device. Only 30% of the participants had previously participated in a clinical trial, however over 90% agreed that they would be willing to participate in future clinical research. Some difficulties were noted in refreshing the browser whenever updates to the website were made. The feedback attained will be used to improve current processes and procedures of the STOPCoV trial as well as share learning experiences to inform future fully decentralized research studies.
format Online
Article
Text
id pubmed-10168576
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-101685762023-05-10 Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey Ravindran, Rizani Szadkowski, Leah Lovblom, Leif Erik Clarke, Rosemarie Huang, Qian Wen Manase, Dorin Parente, Laura Walmsley, Sharon PLOS Digit Health Research Article The Covid-19 pandemic required many clinical trials to adopt a decentralized framework to continue research activities during lock down restrictions. The STOPCoV study was designed to assess the safety and efficacy of Covid-19 vaccines in those aged 70 and above compared to those aged 30–50 years of age. In this sub-study we aimed to determine participant satisfaction for the decentralized processes, accessing the study website and collecting and submitting study specimens. The satisfaction survey was based on a Likert scale developed by a team of three investigators. Overall, there were 42 questions for respondents to answer. The invitation to participate with a link to the survey was emailed to 1253 active participants near the mid-way point of the main STOPCoV trial (April 2022). The results were collated and answers were compared between the two age cohorts. Overall, 70% (83% older, 54% younger cohort, no difference by sex) responded to the survey. The overall feedback was positive with over 90% of respondents answering that the website was easy to use. Despite the age gap, both the older cohort and younger cohort reported ease of performing study activities through a personal electronic device. Only 30% of the participants had previously participated in a clinical trial, however over 90% agreed that they would be willing to participate in future clinical research. Some difficulties were noted in refreshing the browser whenever updates to the website were made. The feedback attained will be used to improve current processes and procedures of the STOPCoV trial as well as share learning experiences to inform future fully decentralized research studies. Public Library of Science 2023-05-09 /pmc/articles/PMC10168576/ /pubmed/37159470 http://dx.doi.org/10.1371/journal.pdig.0000242 Text en © 2023 Ravindran et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Ravindran, Rizani
Szadkowski, Leah
Lovblom, Leif Erik
Clarke, Rosemarie
Huang, Qian Wen
Manase, Dorin
Parente, Laura
Walmsley, Sharon
Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey
title Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey
title_full Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey
title_fullStr Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey
title_full_unstemmed Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey
title_short Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey
title_sort decentralized study of covid vaccine antibody response (stopcov): results of a participant satisfaction survey
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10168576/
https://www.ncbi.nlm.nih.gov/pubmed/37159470
http://dx.doi.org/10.1371/journal.pdig.0000242
work_keys_str_mv AT ravindranrizani decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey
AT szadkowskileah decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey
AT lovblomleiferik decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey
AT clarkerosemarie decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey
AT huangqianwen decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey
AT manasedorin decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey
AT parentelaura decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey
AT walmsleysharon decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey
AT decentralizedstudyofcovidvaccineantibodyresponsestopcovresultsofaparticipantsatisfactionsurvey